# A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

> **NCT06035354** · PHASE1,PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 427 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** AK120
- **DRUG:** AK120
- **DRUG:** Placebo
- **DRUG:** AK120
- **DRUG:** AK120
- **DRUG:** AK120
- **DRUG:** Placebo
- **DRUG:** AK120
- **DRUG:** AK120
- **DRUG:** AK120

## Key facts

- **NCT ID:** NCT06035354
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035354, "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06035354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*